PRINCETON - PDS Biotechnology Corporation (NASDAQ:PDSB) has confirmed plans to commence its VERSATILE-003 Phase 3 clinical trial for a promising cancer immunotherapy within the first quarter of 2025.

Discover the details of the $148.8 million Project Night Owl Managed Service Provider contract awarded by the U.S Air Force to Leidos.

As Samsung prepares to ship its shiny new Galaxy S25s to customers, there is already an Android 15 update available to ...